Article Details
Retrieved on: 2025-04-29 22:45:58
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Among the key components of many treatment regimens are anti-CD20 monoclonal antibodies, such as rituximab, rituximab biosimilars, and obinutuzumab.
Article found on: www.pharmacytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here